Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Aug 2024A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Centre Hospitalier Universitaire de Nice — PHASE2

TrialRECRUITING
Apr 2024An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

TWi Biotechnology, Inc. — PHASE2, PHASE3

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form.
Check the disease page for updates →

Clinical Trial Landscape

2 active trials
1Phase 2
1PHASE2, PHASE3
2Total recruiting
Search clinical trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form

Recent News & Research

No recent news articles indexed yet for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form.
Search PubMed for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form

Browse all Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form news →

Specialist Network

Top 2 by expertise

View all Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form specialists →

Quick Actions